Clinical trials: Anthracycline-induced Cardiac Toxicity
Patients With Cancer
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT04030546
- Testing
- Ivabradine
- Where
- Lithuania
- Volunteers
- 128 people
- Sponsor
- Vilnius University
Doxorubicin Induced Cardiomyopathy
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
- Trial name
- NCT05792293
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma Cancer, Breast Cancer
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or…
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma
- Trial name
- NCT07838649
- Testing
- 68Ga-Galmydar, PET/MRI, 18F-FDG
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Cardiomyopathies, Chemotherapy Effect
Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart…
- Conditions
- Cardiomyopathies, Chemotherapy Effect, Diastolic Dysfunction, Systolic Dysfunction
- Trial name
- NCT05175066
- Testing
- Bisoprolol
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cardiovascular Diseases
Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced Cardiotoxicity
Anthracycline therapy is well-known for its adverse cardiac effects. Anthracycline-induced cardiotoxicity (AIC) is associated with a poor prognosis; since classical heart failure treatment can potentially reverse cardiac…
- Trial name
- Anthracardio (NCT02875171)
- Testing
- Anthracycline administration
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Versailles Hospital
Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and…
- Conditions
- Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity, Anthracyclines
- Trial name
- MUSCLE (NCT05731375)
- Testing
- 31-MRS at 7 Tesla (T)
- Where
- 4 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Cardiotoxicity, Heart Failure
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure.
- Conditions
- Cardiotoxicity, Heart Failure, Neoplasms, Breast Neoplasms
- Trial name
- ML-CardioTox (NCT07191730)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Caen
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Cancer, Breast, Cardiotoxicity
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
Although great progress has been made in treating breast cancer, long-term health may be impaired by cancer therapy. For example, some chemotherapy drugs (e.g., anthracyclines) are known to cause declines in heart health.
- Conditions
- Cancer, Breast, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- EXACT2 (NCT03748550)
- Testing
- Aerobic exercise
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Nova Scotia Health Authority
Breast Cancer, Myocardial Damage
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping
Anthracyclines (e.g. Doxorubicin) are an important and highly effective chemotherapeutic. They are used in various tumor entities and are established for breast cancer treatment.
- Conditions
- Breast Cancer, Myocardial Damage, Cardiotoxicity
- Trial name
- ANKE (NCT03940625)
- Testing
- Cardiac MRI and echocardiography, laboratory parameters
- Where
- Germany
- Volunteers
- 69 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Cardiotoxicity, Heart Failure
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 months…
- Conditions
- Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy
- Trial name
- NCT03155802
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stony Brook University
Neoplasms, Heart Failure
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Anthracyclines are associated with cardiotoxic effects. Previous studies suggest that enalapril, and or carvedilol, protect against cardiovascular effects of these drugs.
- Conditions
- Neoplasms, Heart Failure, Cardiotoxicity, Chemotherapy Effect
- Trial name
- IPAC (NCT03650205)
- Testing
- Ivabradine
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- University of Sao Paulo
Newly Diagnosed Acute Myeloid Leukemia (AML)
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients…
- Trial name
- AML/HMA (NCT07851012)
- Volunteers
- 146 people
- Sponsor
- Assiut University
Childhood Cancer, Cardiac Toxicity
Translating ECHOS2 Into an mHealth Platform
Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low.
- Conditions
- Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
- Trial name
- ECHOS2 (NCT05923242)
- Testing
- Computerized Intervention Authoring Software (CIAS)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Breast Cancer
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives.
- Trial name
- NCT04434404
- Testing
- L-Carnitine 500Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 83 people
- Sponsor
- Horus University
Cardiotoxicity, Childhood Cancer
Prediction of Delayed Toxic Cardiomyopathy in Children
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.
- Trial name
- SpeckleAnthra2 (NCT05781672)
- Testing
- cardiac ultrasound with speckle tracking analysis
- Where
- France
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Leukemia, Cardiac Toxicity
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
It is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations.
- Trial name
- CA2D (NCT01212926)
- Testing
- Echographic analysis of myocardial deformation in 2D strain
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux